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Abstract 
Effects of fusogenic and DNA-binding amphiphilic ompounds on the receptor-mediated gene transfer using asialofetuin-labeled 
liposomes (AF-liposomes) were examined with HepG2 cells and rat hepatocytes in primary culture. AF-liposomes were sufficiently taken 
up by both types of cells through the asialoglycoprotein receptor-mediated endocytosis. In HepG2 cells, bacterial /3-galactosidase (/3-Gal) 
gene expression was observed by transfection using AF-liposomes encapsulating plasmid pCMV/3 DNA (AF-liposome-pCMV/3). By 
addition of dioleoylphosphatidylethanolamine (DOPE) to the liposomal lipid composition (AF-liposome(DOPE)-pCMV/3), the transfec- 
tion efficiency was clearly increased. The effects of DOPE were more conspicuous in the presence of chloroquine in the medium 
throughout the transfection. When pCMV/3 complexed with gramicidin S (pCMV/3(GrS)) was encapsulated (AF-liposome(DOPE)- 
pCMV/3(GrS)) and was transfected to HepG2 cells, an significantly high /3-Gal activity in the cells was observed as compared with that 
in the cells transfected with AF-liposome(DOPE)-pCMV/3. No effects of GrS were found in the transfection using AF-non-labeled control 
liposomes. In primary culture of rat hepatocytes, no /3-Gal gene expression was observed even though AF-liposome(DOPE)-pCMV/3 was 
introduced into the cells prepared from adult rats. However, following the transfection with AF-liposome(DOPE)-pCMV/3, the /3-Gal 
activity was expressed in the cells from immature rats cultured in the medium supplemented with epidermal growth factor and insulin, 
and the transfection efficiency was 2-fold higher than that transfected with pCMV/3 encapsulated in AF-non-labeled control liposomes. 
By the complex formation of pCMV/3 with GrS, the transfection efficiency of AF-Iiposome(DOPE)-pCMV/3(GrS) increased according to 
the increase of GrS in the complex. It was shown that AF-liposome(DOPE)-pCMV/3(GrS) did efficiently introduce and express /3-Gal 
gene in both HepG2 cells and primary hepatocytes in the receptor mediated manner. 
Keywords." Liposome; Asialofetuin; Amphiphilic compound; Receptor mediation; Gene transfer; Hepatocyte; (Rat) 
Abbreviations: AF, asialofetuin; AF-liposomes, AF-labeled liposomes; AF-liposome-pCMV/3, pCMV/3-encapsulated AF-liposomes; DOPE, di- 
oleoylphosphatidylethanolamine; AF-l posome(DOPE)-pCMV/3, pCMV/3-encapsulated AF-liposomes containing DOPE; GrS, gramicidin S;pCMV/3(GrS), 
pCMV/3 complexed with GrS; AF-Iiposome(DOPE)-pCMV/3(GrS), pCMV/3(GrS)-encapsulated AF-liposomes containing DOPE; AgpR, asialoglycopro- 
tein receptors; RME, receptor-mediated en ocytosis; ONPG, O-nitrophenyl-/3-~galactopyranoside; Ins, insulin; Chol, cholesterol; EB, ethidium bromide; 
PC, egg yolk phosphatidylcholine; TMAG, N-(a-trimethylammonioacetyl)-didodecyl-D-glutamate chloride; EGF, epidermal growth factor; DMEM, 
Dulbecco's modified Eagle's medium; EMEM, Eagle's minimum essential medium; FBS, fetal bovine serum; BSA, bovine albumin; DOC, sodium 
deoxycholate; N-liposome(DOPE)-pCMV/3, pCMV/3-encapsulated non-labeled control liposomes containing DOPE; N-liposome(DOPE)-pCMV/3(GrS), 
pCMV/3(GrS)-encapsulated non-labeled control liposomes containing DOPE. 
Corresponding author. 
0005-2736/96/$15.00 © 1996 Elsevier Science B.V. All rights reserved 
SSDI0005-2736(95)00205-7  
52 T. Hara et al. / Biochimica et Biophysica Acta 1278 (1996) 51-58 
1. Introduction 2. Materials and methods 
Advancements in gene therapy depend to a large degree 
on the development of delivery systems capable of effi- 
ciently introducing DNA into the target cells. Although 
significant progress has been made using recombinant 
retroviruses [1,2] or adenoviruses [3,4] for gene delivery, 
concern about the possible production of replication com- 
petent viruses by the recombination [5] and the oncogenic 
effects by random insertion into the host genome [6] has 
encouraged a development of non-viral DNA-mediated 
gene transfer techniques [7-9]. 
We are developing a non-viral methods introducing 
DNA into hepatic parenchymal cells to be a safe and 
reliable gene delivery system that can be used in gene 
therapy. Our strategy has been to exploit the function of 
asialoglycoprotein receptors (AgpR) unique to mammalian 
hepatocytes and capable of recognizing alactose residue 
at the terminal of sugar chain [10-12]. This approach uses 
the combination of asialofetuin (AF) as the specific ligand 
[13] and liposomes as a vehicle which is able to protect 
DNA condensed in its internal space. We have demon- 
strated a successful uptake of AF-labeled liposomes (AF- 
liposomes) by hepatocytes in vitro [14,15] and their spe- 
cific distribution into rat liver in vivo through AgpR [16]. 
Plasmid DNA encapsulated in AF-liposomes was ex- 
pressed in cultured HepG2 cells [17] and mouse liver 
parenchymal cells following portal vein administration [ 18]. 
In these attempts, it has been clarified that the transgene 
expression efficiency was increased by pretreatment of
cells or animals with EDTA encapsulated in AF-lipo- 
somes. We speculated that a large fraction of DNA intro- 
duced into cells by the receptor-mediated ndocytosis 
(RME) would be hydrolyzed by nucleases in the lysosome, 
and that EDTA delivered by the same route as DNA-en- 
capsulated AF-liposomes could reduce lysosomal nuclease 
activity. The degradation of DNA in the lysosome seems 
to be a common problem in various gene transfer tech- 
niques using RME [19]. 
Since the efficiency of viral infection is in large part 
due to fusogenic amino acids on viral membrane proteins, 
we examined whether a fusogenic lipid or membrane 
destabilizing peptide could be used to improve the effi- 
ciency of the transfection using AF-liposomes. Di- 
oleoylphosphatidylethanolamine (DOPE) capable of lead- 
ing a membrane fusion through a formation of hexagonal 
II phase in the membrane [20] was added to the lipid 
composition of AF-liposomes. Gramicidin S (GrS) [21], a 
membrane binding peptide, which can strongly interact 
with DNA by charge interactions [22] and destabilize 
membranes [23,24], was complexed with DNA and encap- 
sulated in AF-liposomes. The ability of AF-liposomes thus 
modified to transfect both hepatoblastoma cell line, HepG2, 
and rat hepatocytes in primary culture was examined using 
a plasmid pCMV/3 DNA as a reporter. 
2.1. Materials 
AF (type I), O-nitrophenyl-/3-D-galactopyranoside 
(ONPG), cytochalasin B, trypsin inhibitor and insulin (Ins) 
were purchased from Sigma (St. Louis, MO). Cholesterol 
(Chol), collagenase and ethidium bromide (EB) were from 
Wako Pure Chemicals (Osaka, Japan). Egg yolk phospha- 
tidylcholine (PC) was obtained from Nippon Fat and Oil 
(Tokyo, Japan), N-(c~-trimethylammonioacetyl)-didodecyl- 
D-glutamate chloride (TMAG) from Sogo Pharmaceutical 
(Tokyo, Japan), DOPE from Avanti Polar Lipids (Alabas- 
ter, AL) and metrizamide from Nycomed Pharma (Oslo, 
Norway). Epidermal growth factor (EGF) was obtained 
from Wakunaga Pharmaceutical (Hiroshima, Japan). Dul- 
becco's modified Eagle's medium (DMEM) and Eagle's 
minimum essential medium (EMEM) were from Nissui 
Pharmaceutical (Tokyo, Japan). DM-160AU medium was 
purchased from Kyokuto Pharmaceutical (Tokyo, Japan), 
fetal bovine serum (FBS) from Moregate Exports 
(Melbourne, Australia) and bovine serum albumin (BSA) 
from Boehringer-Mannheim (Mannheim, Germany). 
[ ~4 C]Cholesteryl o eate and Aquasol-2 were purchased from 
Du Pont New England Nuclear (Boston, MA). All other 
reagents were of analytical grade. 
The plasmid pCMV/3 DNA (7.2 kb) constructed by 
MacGregor and CaskeT [25] was amplified in Escherichia 
coli, isolated by the alkaline method and purified using a 
pZ523 column (5 Prime-3 Prime Inc., Denver, CO). The 
DNA was dissolved in an appropriate volume of 10 mM 
Tris-HCl buffer (THB, pH 8.0) containing 1 mM EDTA. 
No contamination of bacterial cellular DNA was con- 
firmed by 1.0% agarose gel electrophoresis. The concen- 
tration of DNA was determined by the absorbance at 260 
nm, and the DNA solution was diluted to 4 /zg//~l and 
stored at 4°C until use. 
2.2. Preparation of pCMV~ complexes with GrS 
pCMV/3 and GrS complexes (pCMV/3(GrS)) were pre- 
pared according to Legendre et al. [21]. In brief, GrS 
dissolved in dimethyl sulfoxide (20 mg/ml) was diluted 
(× 1/10) with 10 mM THB (pH 7.5). 20 /zl of the diluted 
GrS solution was mixed with 20 /zg of pCMV/3 dissolved 
in 280 /zl of 10 mM THB (pH 7.5). The mixture was 
incubated at room temperature for 30 min, and then 
pCMV/3(GrS) with the weight ratio of GrS/pCMV/3 = 2 
was obtained, pCMV/3(GrS)s with the weight ratio of 0.5, 
1 and 4 were also prepared using 5, 10 or 40 /~1 of the 
diluted GrS solution. 
2.3. Preparation of AF-liposomes encapsulating pCMV~ 
Plasmid pCMV/3 DNA or pCMV/3(GrS) was encapsu- 
lated in AF-liposomes composed of PC/TMAG/Chol = 
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5:2:3 (AF-liposome-pCMV/3) or PC/TMAG/DOPE= 
2:1:2 (A F - l iposom e(D O PE) -pC M V/3, AF -  
liposome(DOPE)-pCMV/3(GrS)) by a tandem combination 
of the detergent removal and freeze-thaw methods [ 17]. AF 
(125 /zg) was incubated with 5-fold mol of N-palmitoyl- 
oxysuccinimide in 25 /xl of 10 mM THB (pH 7.5) contain- 
ing 2% sodium deoxycholate (DOC) at 37°C for 12 h to 
prepare palmitoyl-AF. 1 /zmol of lipids in chloroform 
were dried under reduced pressure into a thin lipid film on 
the inner face of a glass tube. Following hydration with 50 
/zl of 10 mM THB (pH 7.5), the DOC solution of palmi- 
toyl-AF was added and the mixed micelles were prepared 
by vigorous vortexing. The DOC was dialyzed out to 10 
mM THB (pH 7.5) for 24 h, and AF-liposomes encapsulat- 
ing the buffer were formed. The empty liposomes were 
sonicated for 5 min in a bath type sonicator (Branson 
B-2200, Tokyo, Japan). 20 /zg of pCMV/3 diluted with 10 
mM THB (pH 7.5) to 300 /zl or pCMV/3(GrS) was added 
to the liposome suspensions and lyophilized. After rehy- 
dration with 20 /zl of 10 mM THB (pH 7.5) containing 
0.9% NaCl, freeze (at - 80°C)-thaw (at 0°C) was repeated. 
pCMV/3 or pCMV/3(GrS)-encapsulated non-labeled con- 
trol l iposomes (N-l iposome(DOPE)-pCMV/3, N- 
liposome(DOPE)-pCMV/3(GrS)) were also prepared with- 
out palmitoyl-AF. These liposomes encapsulating DNA 
were purified by metrizamide-gradient flotation as de- 
scribed previously [17]. The concentration of DNA and 
phospholipids in the liposomal fractions were determined 
according to the method of Boer [26] and Chen et al. [27], 
respectively, following solubilization of liposomes by Tri- 
ton X-100 (final concentration 0.5%). By this procedure, it 
was ascertained that more than 85% of used pCMV/3 or 
pCMV/3(GrS) was associated to liposomes and about 65% 
of them became resistance to DNase I digestion (50 
#g/ml ,  37°C, 30 rain), indicating their encapsulation i to 
the internal aqueous phase of liposomes, irrespective of the 
liposomal lipid composition and AF-labeling. 
2.4. Cells 
HepG2 cells, human hepatoblastoma cell line [28], were 
grown in the DM-160AU medium supplemented with 10% 
FBS, 2 mM L-glutamine, 15 mM NaHCO 3 and 60 p~g/ml 
streptomycin in 150 mm plastic culture dishes (Nunc, 
Roskilde, Denmark) at 37°C under an atmosphere of 
CO2/air = 5:95. The cells at semi-confluence (4-6 days 
growth) were scraped from dishes with addition of an 
aqueous olution of 0.25% trypsin containing l mM EDTA, 
spun down, and washed. The cells were dispersed (8. 
105/ml) and seeded (5 ml each) in 60 mm plastic culture 
dishes. 
Hepatocytes in primary culture were prepared from 
male adult (8 week) and immature (3 week) Wistar rats 
according to the method of Moldeus et al. [29] with a 
minor modification. A cannula was inserted into portal 
vein of anesthetized rats and pre-perfusion of the liver was 
immediately started with a perfusion buffer (8 g of NaC1, 
0.4 g of KC1, 0.078 g of NaH2PO 4, 0.151 g of Na 2 HPQ.  
12 H20, 2.38 g of Hepes, 0.35 g of NaHCO3/liter, pH 
7.4) supplemented with 5 mM glucose and 0.5 mM EGTA 
at a flow rate of 30 ml/min. When the blood was fully 
removed, the perfusion buffer was changed to the same 
buffer containing 0.5 mg/ml collagenase, 50 #g/ml  
trypsin inhibitor, and 5 mM CaC12, and the pevfusion was 
continued for another 6 min. At the end of the perfusion, 
the liver was excised, immersed in ice-cold EMEM supple- 
mented with 0.03% L-glutamine and 0.4% NaHCO 3 and 
dispersed by gentle shaking. The cell dispersion was fil- 
tered through a cotton gauze and the cells were collected 
by centrifugation at 50 × g for 1 rain at 4°C. Following 
washing four times, the cells were dispersed in the normal 
medium, DMEM containing 10 -9 M Ins, 10 -9 M dexa- 
methasone, 0.25 /zg/ml fungizone and 100 /xg/ml 
streptomycin, 1 mg/ml penicillin and 20 mM NaHCO 3, or 
the modified medium, the normal medium not containing 
dexamethasone but supplemented with 10 v M Ins, 20 
ng/ml EGF, 90 /,tg/ml L-alanine, 50 /~g/ml L-glutamic 
acid, 2 /zg/ml L-ascorbic acid, 30 ~g/ml  L-aspartic acid 
and 30 /~g/ml L-proline, at a density of 6. 10-S/ml for 
adult or 5. 105/ml for immature rat hepatocytes, and 
seeded (4 ml each) in 60 mm collagen coating culture 
dishes (KOKEN, Tokyo, Japan). 
2.5. Uptake of AF-liposomes by hepatic ells 
HepG2 cells (4. 10 6) and adult rat hepatocytes (2.4. 
10 6) were pre-cultured for l day. After the medium was 
changed to 1 ml of the FBS-free medium, AF-liposomes 
containing the tracer amount of [l~C]cholesteryl o eate 
were added with or without 2 mg of free AF and incubated 
at 37°C in 5% CO 2 for 18 h. At the indicated points of 
time, the cells were washed with ice-cold medium, lysed 
with 0.5 ml of 1 N KOH and neutralized with 0.6 ml of 1 
N acetic acid. The radioactivity of 1 ml of cell lysates was 
counted. 
2.6. Transfection and tg-Gal assay 
After HepG2 cells (4. 10 6) and adult (2.4. 10 6) and 
immature rat hepatocytes (2. 10 6) were pre-cultured for 1 
day, the medium was removed and the cells were washed 
three times with FBS-free medium. Liposomes encapsulat- 
ing pCMV/3 or pCMV/3(GrS) were diluted up to 1 ml with 
FBS-free medium, and then added to the cells and incu- 
bated at 37°C in 5% CO 2 for 16 h. When the liposomes 
were added together with chloroquine or cytochalacin B, 
incubation was shortened to 6 h. At the end of the incuba- 
tion, the medium was removed and the cells were further 
cultured for 48 h in the fresh medium containing 10% 
FBS. The cells were washed twice and were scraped from 
dishes into ice-cold 20 mM THB (pH 7.5) containing 150 
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mM NaC1 and 1 mM EDTA and centrifuged at 2500 × g 
for 5 min. The cells, resuspended in 0.4 ml of 0. l M PBS 
(pH 7.5), were disrupted by five freeze-thaw cycles using 
dry ice/methanol and a 37°C water bath. Following cen- 
trifugation at 14000 × g for 15 rain, a portion of the 
supernatant was assayed for protein content by the Brad- 
ford microprotein assay (Bio-Rad, Lichmond, CA). /3-Gal 
activity was assayed according to Miller [30] as follows: 
the supernatants containing 100 /zg of protein were diluted 
up to 231 /xl with 0.1 M PBS (pH 7.5), mixed with 3 /xl 
of 0.1 M MgCI 2 containing 4.5 M /3-mercaptoethanol, and 
66 /zl of 0.4% ONPG in 0.1 M PBS (pH 7.5), and 
incubated at 37°C for 30 min. The reaction was stopped by 
addition of 500 /zl of 1 M Na2CO 3. The optical density of 
the reaction mixture was measured at 420 nm. The enzyme 
activity was expressed as a unit (one nmol of O-nitrophenol 
liberated from ONPG per min) per mg protein. 
3. Results 
3.1. AgpR-mediated uptake of AF-liposomes by hepatic 
cells 
AF-liposomes containing a tracer amount of 
[14C]cholesteryl oleate were added to HepG2 cells or adult 
rat hepatocytes in primary culture and incubated at 37°C. 
At the indicated points of time, the radioactivity associated 
with the cells was determined as uptake indicating the sum 
of the AF-liposomes adsorbed to and incorporated into the 
cells. As shown in Fig. 1, the cell-associated radioactivity 
increased with lapse of time and reached about 50% of the 
added dose in HepG2 cells and about 74% in primary 
hepatocytes for 18 h. By addition of excess free AF, the 
cell-associated radioactivities were reduced by about 80% 
in HepG2 cells and by 60% in primary hepatocytes. 
Table 1 
Effects of DOPE on the transfection of hepatocytes by AF-liposomes 
DNA /3-Galactosidase activity (units/mg protein) a 
( /zg/dish) HepG2 cells primary hepatocytes b 
AF-liposome- AF-liposome AF-liposome 
pCMV/3 c (DOPE)-pCMV/3 d (DOPE)-pCMV/3 d 
0 2.36__+0.22 2.36__+0.22 1.89_+0.26 
1.25 2.81 _+0.31 4.01 _+0.46 * ND 
2.50 3.65 _+0.24 5.61 +0.63 * * ND 
5.00 6.89_+0.52 13.0_+ 1.18 * * * 2.10_+0.31 
10.0 11.0-+ 1.21 15.4-+2.07 * ND 
15.0 12.8_+1.06 20.0_+2.14 * ~ 2.37_+0.25 
'~ The mean from three experiments_+ S.D. 
b Hepatocytes from adult rats were cultured in normal medium (DMED 
supplemented with 10% FBS). 
AF-liposome-pCMV/3 (23.6 /zg DNA//xmol lipids) was added. 
d AF-liposome (DOPE)-pCMV/3 (26.3/~g DNA//xmol lipids) was added. 
ND, not determined. 
Statistically significant differences from AF-liposome-pCMV/3: P < 0.05 
(*), P<O.01 (**),  P<O.O01 (***) .  
3.2. Effects of DOPE on the tran~fection efficiency of 
AF-liposomes encapsulating pCMV[~ 
Hepatic cells were transfected with various amounts of 
AF-liposome-pCMV/3 or AF-liposome(DOPE)-pCMV/3. In 
HepG2 cells, /3-Gal gene expression was observed for both 
AF-liposome-pCMV/3 and AF-liposome(DOPE)-pCMV/3, 
and /3-Gal activity in the cells increased with increasing 
DNA added to the cells (Table 1). Transfection efficiency 
of AF-liposome(DOPE)-pCMV/3 was 1.4-1.9-fold higher 
than that of AF-liposome-pCMV/3 at any amount of DNA 
added. But, no increase in /3-Gal activity was observed in 
adult rat hepatocytes in primary culture transfected with 
AF-liposome(DOPE)-pCMV/3. 
Effects of chloroquine on the transfection efficiency of 
AF-liposome-pCMV/3 and AF-liposome(DOPE)-pCMV/3 
were examined in HepG2 cells. As shown in Fig. 2, 
80 
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Time (h) 
Fig. 1. Uptake of AF-liposomes by hepatic cells. HepG2 cells (circle) or 
adult rat hepatocytes in primary culture (triangle) were incubated with 
[14C]AF-liposomes (20 nmol lipid/106 cells) at 37°C for indicated time 
in the absence (closed symbol) or presence (open symbol) of free AF (0.5 
mg/106 cells). Each point presents the mean from three experiments_+ 
S.D. statistically significant differences from the absence of free AF: 
P < 0.001(* ). 
.,_>, 
.> 
~..= 
0 25 50 75 1 O0 
Chloroquine (pM) 
Fig. 2. Effects of chloroquine on the transfection efficiency of AF-lipo- 
somes encapsulating pCMV/3. HepG2 cells were transfected with AF- 
liposome-pCMV/3 (4.0 /Lg DNA/0.17 /~mol lipid, sparsely hatched 
column) or AF-liposome(DOPE)-pCMB/3 (4.0 /xg DNA/0.18 /xmol 
lipid, closely hatched column) in the medium containing indicated con- 
centration of chloroquine for 6 h. Each column presents the mean from 
three experiments -+S.D. 
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Table 2 
Transfection of primary hepatocytes with AF-liposome (DOPE)-pCMV/3 
in the presence of chloroquine 
DNA a 
(/zg/dish) 
/3-Galactosidase activity (units/rag protein) b 
adult immature immature 
DMEM " DMEM d modified DMEM e 
0 1.78+0.28 2.07_+0.22 1.87_+0.18 
1.0 ND ND 2.24 _+ 0.38 
2.0 ND ND 3.08 _+ 0.49 * 
4.0 2.18_+0.29 2.64_+0.28 3.4l _+0.26 * * * 
8.0 2.06_+0.24 2.83-+0.17 #* ~ 3.61 -+0.19 *- . . . .  
16 1.74-+0.33 2.69_+0.23 # 2.81 _+0.21 * * 
~AF-liposome (DOPE)-pCMV/3 (28.6 /xg DNA/ / tmol  lipids) were 
added with 25 /zM chloroquine. 
b The mean from three experiments + S.D. 
c Hepatocytes from adult rats were cultured in normal medium (DMEM 
supplemented with 10% FBS). 
Hepatocytes from immature rats were cultured in normal medium 
(DMEM supplemented with 10% FBS). 
Hepatocytes from immature rats were cultured in modified medium 
(DMEM supplemented with 10% FBS, EGF and Ins). 
ND, not determined. 
Statistically significant differences from without DNA: P < 0.05 (*), 
P < 0.01 ( * * ), P < 0.001 ( * * * ); between adult and immature: P < 0.05 
(#); between ormal and modified medium: P < 0.05 (*), P < 0.01 (5*). 
transfection efficiencies of both AF-liposome-pCMV/3 and 
AF-liposome(DOPE)-pCMV/3 were enhanced epending 
upon the concentration of chloroquine in the medium, and 
almost the maximum effect was observed at 75 /zM or 
more. However, the degree of enhancement bychloroquine 
was markedly different between the transfection by AF- 
liposome-pCMV/3 and AF-liposome(DOPE)-pCMV/3, and 
a greater effect was observed in the latter with about 5-fold 
increase in /3-Gal activity at 75 /zM chloroquine, com- 
pared with only 2-fold increase in the former. 
3.3. Transfection of primary hepatocytes 
Hepatocytes from adult and immature rats in primary 
culture were transfected with AF-liposome(DOPE)- 
pCMV/3 in the presence of 25 /zM chloroquine. As shown 
in Table 2, no increase in /3-Gal activity was observed in 
adult rat hepatocytes, while /3-Gal activity of immature rat 
hepatocytes increased with increasing DNA added to the 
cells irrespective of their culture medium, and the maxi- 
mum transfection efficiency was obtained in the immature 
rat hepatocytes cultured in the modified medium contain- 
ing EGF and Ins when 8 /zg DNA of AF- 
liposome(DOPE)-pCMV/3 was introduced. 
In immature rat hepatocytes cultured in the modified 
medium, the transfection eff ic iency of AF- 
liposome(DOPE)-pCMV/3 was compared with that of N- 
liposome(DOPE)-pCMV/3. As shown in Fig. 3, the /3-Gal 
gene expression levels in the cells transfected with AF- 
liposomes were about 2-fold higher than that in the cells 
transfected with N-liposomes. By addition of free AF, the 
transfection efficiency with AF-liposomes was signifi- 
cantly reduced to the same level as that of N-liposomes. 
Surprisingly, /3-Gal activity at day 6 in the cells trans- 
fected with AF-liposome(DOPE)-pCMV/3 was signifi- 
cantly higher than at day 2. 
3.4. Effects q[ pCMVt~ complex with GrS on the transfec- 
tion efficiency 
Plasmid pCMV/3 DNA (20 /zg) was complexed with 
GrS (40 /.tg), encapsulated in liposomes and introduced 
into HepG2 cells. In the case of AF-liposomes, /3-Gal 
activity was considerably enhanced by the transfection 
with AF-Iiposome(DOPE)-pCMV/3(GrS), and showed 
Control 
AF-liposome 
(DOPE)-pCMVI3 
AF-liposome 
(DOPE)-pCMVI3 + AF 
N-liposome 
(DOPE)-pCMVI3 
AF-liposome 
(DOPE)-pCMV~ 
l , 
= i i i 
0 1 2 3 4 5 
~Galactosidase activity 
(units/mg protein) 
Fig. 3. Transfection of primary hepatocytes with AF-liposome(DOPE)- 
pCMV/3. Immature rat hepatocytes in primary culture were transfected 
with AF-liposome(DOPE)-pCMV/3 (8.0 /xg DNA/0.28 /,tmol lipid) with 
or without free AF (2 rag) or N-liposome(DOPE)-pCMV/3 (8.0 /xg 
DNA/0.28 /zmol lipid) in the presence of chloroquine (25 NM). /3- 
Galactosidase activity was assayed at day 2 (closely hatched column) or 
at day 6 (sparsely hatched column). Each column presents the mean form 
three experiments _+S.D. statistically significant differences from AF- 
liposome(DOPE)-pCMV/3 at day 2: P < 0.05 (*), P < 0.01 (~ * ), P < 
0.01 ( *** ) .  
u 
- - -  a b - -  a b 
Control  AF - l iposomes  N- l iposomes  
Fig. 4. Effects of GrS on the transfection efficiency of liposomes. HepG2 
cells were transfected with liposomes encapsulating pCMV/3 (sparsely 
hatched column) or pCMVfl(GrS) (closely hatched column) in the pres- 
ence of free AF (2 mg/ml ,  a) or cytochalasin B (5 /zg/ml, b). AF-lipo- 
some(DOPE)-pCMVfl (4.0 /zg DNA/0.16 /zmol lipid), AF- 
liposome(DOPE)-pCMVfl(GrS) (4.0 /zg DNA/0. I  8 /xmol lipid), N-lipo- 
some(DOPE)-pCMV/3 (4.0 /xg DNA/0 .13  /zmol lipid), N- 
liposome(DOPE)-pCMVfl(GrS) (4.0 /.tg DNA/0.25 ~mol lipid). Each 
column presents the mean from three experiments _+S.D. statistically 
significant differences from the cells transfected with pCMV/3(GrS)-en- 
capsulated liposomes: P < 0.01 ( ~ ), P < 0.001 ( * * ). 
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Fig. 5. Effects of GrS content on the transfection efficiency of AF-lipo- 
some(DOPE)-pCMV/3(GrS). Immature rat hepatocytes in primary culture 
were transfected with AF-liposome (DOPE)-pCMVfl(Grs) (0, 4.0 /~g 
DNA/0.14 /~mol lipid; 0.5, 4.0 p~g DNA/0.17 /zmol lipid; 1, 4.0 gg 
DNA/0.16 /~mol lipid; 2, 4.0 /~g DNA/0.15 /~mol lipid; 4, 4.0 p~g 
DNA/0.16 ,u, mol lipid). Each column presents the mean from three 
experiments + S.D. 
about 3-fold higher /3-Gal activity than that of AF-lipo- 
some(DOPE)-pCMV/3 (Fig. 4). By addition of excess free 
AF, the transfection efficiency of AF-liposome(DOPE)- 
pCMVfl(GrS) was decreased to the same level as that of 
N-liposome(DOPE)-pCMVfl(GrS). Although the addition 
of cytochalasin B in the medium also decreased the trans- 
fection efficiency of AF-liposome(DOPE)-pCMV/3(GrS), 
the degree of inhibition was smaller than that by AF. In 
N-liposomes, no increase in fl-Gal activity was observed 
even when the cells were transfected with N- 
liposome(DOPE)-pCMVfl(GrS). The addition of AF ex- 
hibited no effect and that of cytochalasin B brought about 
a significant increase in the transfection efficiency of 
N-liposome(DOPE)-pCMVfl (GrS). 
pCMVfl(GrS) complexes with various GrS contents 
were encapsulated and the effects of GrS content on the 
transfection with AF-liposome(DOPE)-pCMV/3(GrS) were 
examined using immature rat hepatocytes. As shown in 
Fig. 5, the transfection ef f ic iency of AF- 
liposome(DOPE)-pCMVfl(GrS) was increased with in- 
creasing GrS content in the complex. An extremely high 
/3-Gal activity was found in the cells transfected with 
AF-liposome(DOPE)-pCMVfl(GrS) with the GrS/pCMVfl 
weight ratio of 4, and the activity was about sevenfold of 
that in the cells transfected with AF-liposome(DOPE)- 
pCMV/3 without GrS. 
4. Discussion 
HepG2 cells and rat hepatocytes in primary culture 
were used as transformed and non-transformed cells, re- 
spectively, in this report. These cells are quite different in 
various properties uch as the cell surface expressed pro- 
teins and proliferation activity. With primary cells in cul- 
ture, including hepatocytes, uccessful transfection and 
expression of foreign DNA have been generally difficult to 
achieve [31], and there is no report concerning the transfec- 
tion of primary hepatocytes using receptor-mediated gene 
transfer techniques. 
As clearly shown in Fig. 1, AF-liposomes were suffi- 
ciently taken up by both HepG2 cells and adult rat hepato- 
cytes in primary culture. The strong inhibition in the 
uptake by free AF indicates that interactions with the 
AgpR are largely involved in the association of AF-lipo- 
somes with both types of cells. In this experiment, it was 
determined beforehand that the association constant (K a) 
and number (n) of AgpR on the primary hepatocytes were 
1.8. 109 M - !  and 1.1 • 105/cell, respectively. These val- 
ues are almost the same as those reported for isolated rat 
hepatocytes [32] and are somewhat higher than those of 
HepG2 cells previously determined as K a = 2.8 • 10 8 M-1  
and n = 2.9 - 104/cell in our laboratory [33]. As predicted 
from their binding parameters, the uptake by primary 
hepatocytes were slightly higher than that by HepG2 cells 
(Fig. 1). However, in the transfection with AF- 
liposome(DOPE)-pCMV/3, a substantial fl-Gal gene ex- 
pression was observed only in HepG2 cells (Table 1). 
These results indicate that the reason for no transgene 
expression in adult rat hepatocytes in primary culture 
could not be attributed to their ability to take up AF-lipo- 
some-pCMV/3. Moreover, plasmid pCMV/3 DNA contains 
cytomegalovirus immediate early promoter, which has been 
reported to exhibit a high promoter activity in adult rat and 
human hepatocytes [34,35]. 
It is known that DOPE is a hexagonal II phase-forming 
lipid under the physiological conditions and is able to 
promote membrane fusion [20]. Therefore, DOPE has been 
widely used in various cationic liposomes for transfection 
such as Lipofectine [36]. The significantly higher transfec- 
tion efficiency of AF-liposome(DOPE)-pCMV/3 in HepG2 
cells than that of DOPE deficient AF-liposome-pCMVfl 
(Table 1) may be attributed to the fusogenic activity of 
DOPE, and the importance of liposome-cell fusion, whether 
with plasma membrane or endosome/lysosome em- 
brane, was suggested in the efficient transfection using 
AF-liposomes. The DOPE effect was considerably en- 
hanced by chloroquine (Fig. 2), a lysosomotropic agent 
[37]. It has been reported that a ligand endocytosed via 
AgpR is transferred to the lysosome and degraded rapidly 
[38]. In the presence of chloroquine, lysosomal function 
could be inhibited and AF-liposome (DOPE)-pCMVfl 
could be retained in the endosome/lysosome for a long 
period. The fusion with the membrane of the organella 
could occur and encapsulated pCMV/3 could be released 
into the cytoplasm. 
In this experiment, cells were transfected in an FBS-free 
medium. It has been reported that a considerable r duction 
of transfection efficiency by the serum components was 
observed in cationic liposomes [39]. In our previous report 
[17], transfection of HepG2 cells using AF-liposomes 
slightly inhibited by addition of negatively charged fetuin 
but not by bovine serum albumin, indicating that the 
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inhibition may due to the reduction of non-specific harge 
interaction of AF-liposomes with cells. Hence, addition of 
FBS would somewhat lower the transfection efficiency of 
AF-liposomes but the transfection via the specific interac- 
tion with AgpR may not be affecte0 
The order of transgene xpressmn efficiency was as 
follows; HepG2 cells > immature rat hepatocytes cultured 
in the modified medium containing EGF and Ins > 
immature rat hepatocytes cultured in the normal medium 
and no expression in adult rat hepatocytes (Tables 1 and 
2). EGF and Ins are able to promote the cells in GI to S 
and facilitate cellular proliferation [40]. Therefore, the 
order was consistent with that of their proliferation activi- 
ties. It is speculated that exogenous DNA molecules might 
migrate into the nucleus during the disappearance p riod 
of the nuclear membrane, because their volume is too large 
to diffuse through nuclear pores [41]. It may be considered 
as another possibility that the transport of some endoge- 
nous nuclear proteins occurs at a high level when the cells 
are proliferating and exogenous DNA interact with the 
endogenous nuclear proteins and is co-introduced into the 
nucleus by means of active process [42-44]. Since adult 
liver consists of G 0 cells, it is important to elucidate the 
transport mechanism of foreign DNA into the nucleus to 
achieve in vivo gene transfer into hepatocytes. 
Gene transfer and expression by AF-liposome (DOPE)- 
pCMV/3 observed in primary hepatocytes were demon- 
strated to occur partially via AgpR (Fig. 3). The expression 
in the presence of free AF remained at the same level as 
that of N-liposome (DOPE)-pCMVJ3, and these were prob- 
ably caused by the charge interaction between liposomes 
possessing positive charge and cells having negative sur- 
face charge. Surprisingly,/3-Gal ctivity in the cells showed 
a higher level on day 6 rather than on day 2 following 
transfection with AF-liposome(DOPE)-pCMV/3 (Fig. 3). 
However, whether the expression is transient or stable is a 
matter of great importance and remains to be elucidated. 
GrS, an amphipathic yclic decapeptide having posi- 
tively charged two ornithine residues, can interact with 
DNA [22] or destabilize biological membranes [23,24]. 
Legendre t al. reported an excellent transfection technique 
using DNA-GrS complex, and this complex was non- 
specifically adsorbed on the cells in culture and directly 
penetrated into the cytoplasm and the maximum transfec- 
tion efficiency was obtained at an equivalent charge ratio 
between the DNA and GrS [21]. The transfection effi- 
ciency of AF-liposomes was also improved by GrS (Fig. 
4), and the highest transfection efficiency was observed 
when pCMV/3(GrS) with the weight ratio of GrS/pCMV/3 
= 4 corresponding to the charge ratio of GrS/pCMV/3 -- 2 
was encapsulated (Fig. 5). The discrepancy may come 
from the difference in the uptake mechanism. A significant 
reduction in the transfection efficiency of AF- 
liposome(DOPE)-pCMV/3(GrS) was observed by treat- 
ment with cytochalasin B (Fig. 4), which is well known to 
inhibit phagocytosis through the microfilament function 
[45] and has been demonstrated to inhibit incorporation of 
AF [46] or AF-liposomes [17] into hepatocytes, suggesting 
that GrS may exhibit its membrane destabilizing effect 
after on going endocytosis i over. The detailed mecha- 
nism is considered as follows; (1) AF-liposome(DOPE)- 
pCMV/3(GrS) taken up by RME and incorporated into the 
endosome is transferred to the lysosome, (2) liposomes are 
degraded and pCMV/3(GrS) complex is released from 
liposomes, (3) pCMV/3(GrS) complex penetrates the lyso- 
somal membrane by destabilizing the membrane, and (4) 
the complex is transferred into the cytoplasm before its 
hydrolysis. This possible mechanism is also supported by 
the results that the transfection was almost completely 
inhibited by addition of free AF and that GrS had no 
effects on the transfection using N-liposomes (Fig. 4), 
which were not incorporated into hepatocytes by endocyto- 
sis as was apparent from no inhibition of the uptake by 
cytochalasin B [17]. The reason for an incomplete inhibi- 
tion of the transfection with AF-liposome(DOPE)- 
pCMV/3(GrS) and an enhancement i  the transfection with 
N-liposome(DOPE)-pCMV/3(GrS) by cytochalasin B is 
unclear but a few direct penetration of the liposomes 
through the plasma membrane into the cytoplasm may 
possibly be enhanced. It was reported that cytochalasin B 
promote the transfection efficiency of lipopolylysine con- 
taining cationic liposomes [47]. 
There is an excellent work to improve the efficiency of 
receptor-mediated gene transfer by exploiting the fuso- 
genic and endosomolytic activity of replication defective 
adenovirus particles [48]. This technique allowed DNA to 
escape efficiently from the lysosomal degradation and 
could enhanced elivered gene expression in a variety of 
cultured cells, but could not be used in in vivo gene 
transfer because of a high antigenicity of the viral particles 
and their capture and degradat:,,n by reticuloendothelial 
systems [49]. AF-Iiposome(DOPE)-pCMV/3(GrS) de- 
scribed here contains no viral components and is relatively 
easy to prepare. Immunogenisity of the complexes of DNA 
and GrS has not been cleared, but it would be masked by 
encapsulation them into liposomal ipid bilayers. Leakage 
of pCMV/3 from AF-liposome(DOPE)-pCMVI3(GrS) was 
less than 15% in mouse plasma at 37°C for one day in 
vitro. Since the transfer of AF-liposomes from the blood 
circulation into the liver is very rapid ( t l /2  < 2 rain) [16], 
intravenously injected AF-liposome(DOPE)-pCMV/3(GrS) 
could be incorporated into hepatocytes a  an intact form. 
These emphasize the possibility of AF-liposomes as a liver 
specific gene transfer vector for i~. vivo gene therapy. 
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